No Data
There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 33% Price Jump
TEDA BIOMEDICAL (08189): Adjusted offering price to HKD 0.375, resuming trading on February 10.
TEDA BIOMEDICAL (08189) announced the issue regarding the placement of up to 0.2394 billion shares under the general authorization.
Express News | Tianjin TEDA Biomedical Engineering Co - Trading in Shares of Co Will Be Halted With Effect From 9 Am on 6 Feb Pending Announcement
TEDA BIOMEDICAL (08189.HK) plans to offer a discount of about 18.46% to place up to 0.239 billion shares, raising a net amount of 63 million Hong Kong dollars.
On January 16, Gelonghui announced that TEDA BIOMEDICAL (08189.HK) entered into a placement agreement with the placement agent on January 16, 2025. According to this agreement, the placement agent conditionally agrees to use its best efforts to procure no fewer than six (6) subscribers (who, along with their ultimate beneficial owners, must be independent third parties) to subscribe for up to 239,400,000 placement shares at a placement price of HKD 0.265 per share. The maximum number of placement shares, 239,400,000 shares, represents approximately 12.64% of the company’s existing issued share capital as of the date of this announcement.
Express News | Tianjin TEDA Biomedical Engineering - to Place 239.4 Mln Placing Shares at HK$0.265 per Share
Citic sec: Global demand remains strong, and the leading potash fertilizer producer's production cut may raise prices.
Citic sec predicts that the supply and demand for global potassium fertilizer will be tight in 2025, and potassium fertilizer prices are expected to rebound from the bottom.
